Steranabol Ritardo History
Oxabolone was first described in 1934. It-was finally developed into a long-acting injectable medication during the 1960's, sold by Farmitalia Carlo Erba in Italy and Germany as Steranabol-Ritardo and Steranabol-Depot, respectively. This relatively mild nandrolone derivative was used mainly to treat osteoporosis, although it has also been indicated when there was a need for a proteinsparing anabolic agent. It appears to have exhibited a very favorable clinical record, having been used effectively in men, women, the elderly, and children with minimal side effects for several decades. By all accounts, the drug was very safe. There is a great lack of information on this agent in the medical literature, however, being that it was used in a small number of markets only. As such, there is much less data to draw from than with many of the more widely used compounds.
Pharmacia acquired Farmitalia in 1993, at the time one of the largest pharmaceutical conglomerates in the world. Two years later, Pharmacia would go on to merge with Upjohn, another long-standing giant in the drug business. The Steranabol-Depot brand from Germany had been discontinued years earlier, but the Italian product remained on the market well after this corporate transition. For several years it was sold in Italy as a Pharmacia & Upjohn product. Steranabol Ritardo too was eventually discontinued, however, and would be gone by the time Pfizer acquired Pharmacia in 2003.The drug has been out of commerce for long enough now that it has been effectively removed from the black market. The dosage of this product was considerably low anyway (12.5 mg/ml), and as such was never very popular among athletes. Since this was the last remaining prescription drug product to contain oxabolone cypionate worldwide, this marked the commercial end to this steroid. Note that although this agent was unknown to U.S. Federal lawmakers before, it was added to the Anabolic Steroid Control Act in 2005.
How is Steranabol Ritardo Supplied
Oxabolone cypionate is no longer available as a commercial agent. When produced (Steranabol Ritardo) it contained 12.5 mg/ml of steroid in a 2 mL glass ampule.
Structural Characteristics of Steranabol Ritardo
Oxabolone is a modified form of nandrolone. It differs by the introduction of a hydroxyl group at carbon 4, which inhibits aromatization, reduces relative steroid androgenicity, and eliminates progestational activity. Oxabolone cypionate contains boldenone modified with the addition of carboxylic acid ester (cyclopentylpropionic acid) at the 17-beta hydroxyl group, so that the free steroid is released more slowly from the area of injection. Oxabolone cypionate is designed to provide a peak release of oxabolone within a few days after injection, and sustain hormone release for approximately 14-21 days.
Steranabol Ritardo Side Effects (Estrogenic)
Oxabolone is not aromatized by the body, and is not measurably estrogenic. Estrogenic side effects such as increased water retention, fat gain, and gynecomastia are not likely with use. Note that as a 4-hydroxy steroid, this agent may actually inhibit the aromatase enzyme by competitively inhibiting the binding and conversion of other aromatizable substrates. As such, it may actually impart a measurable anti-estrogenic effect. This trait is unconfirmed with oxabolone, but well understood with 4-hydroxyandrostendione. It is of note that in spite of it being a 19-nortestosterone analog, oxabolone has no significant progestational activity.
Steranabol Ritardo Side Effects (Androgenic)
Although classified-as an anabolic steroid, androgenic side effects are still possible with this substance. This may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss. Women are also warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement. Additionally, oxabolone is not extensively metabolized by the 5-alpha reductase enzyme, so its relative androgenicity is not greatly altered by the concurrent use of finasteride or dutasteride. Note that oxabolone is primarily anabolic in nature, and is comparably less likey to produce androgenic side effects than more androgenic agents such as testosterone, methandrostenolone, and fluoxymesterone.
Steranabol Ritardo Side Effects (Hepatotoxicity)
Oxabolone is not a cl 7-alpha alkylated compound, and not known to have hepatotoxic effects. Liver toxicity is unlikely.
Steranabol Ritardo Side Effects (Cardiovascular)
Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDLIbad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Oxabolone should have a stronger negative effect on the hepatic management of cholesterol than testosterone or nandrolone due to its non-aromatizable nature, but a much weaker impact than c-17 alpha alkylated steroids. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.
To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.
Steranabol Ritardo Side Effects (Testosterone Suppression)
All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Without the intervention of testosterone-stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.
Steranabol Ritardo Administration (Men)
Oxabolone cypionate is generally used in clinical doses ranging from 25-50 mg per application, given once every 1 to 3 weeks. Effective doses for physique- or performance-enhancing purposes fall in the range of 100-300 mg perweek,takenfor6-12 weeks. At 25 mg per 2 mL ampule, however, reaching the higher (more effective) doses is difficult. Instead, many would use this steroid as more of an adjunct to an already running stack. At 3-4 ampules per week, or 75-100 mg in total, this steroid is generally strong enough for the user to notice some level of hardening and fat loss on top of the effects of other agents.
Steranabol Ritardo Administration (Women)
Oxabolone cypionate is used in clinical doses ranging from 25-50 mg per application, given once every 1 to 3 weeks. An ideal dosage of .5 mg/kg of bodyweight has been determined for the stimulation of growth in children. Effective doses for physique- or performance enhancing purposes fall in the range of 25-50 mg per week, taken for no longer than 6-8 weeks.
Steranabol Ritardo Availability
Oxabolone cypionate is not available as a prescription agent at this time, in any part of the world.
Wlliam Llewellyn (2017) - Anabolics